4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC). (September 2015) - Carducci, M.; Armstrong, A.; Pili, R.; Ng, S.; Huddart, R.; Agarwal, N.; Khvorostenko, D.; Lyulko, O.; Brize, A.; Vogelzang, N.J.; Delva, R.; Harza, M.; et al.